



Prior Authorization
<p>JOHNS HOPKINS HEALTHCARE (MEDICAID) Lovenox - Priority Partners MCO</p> <p>This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Johns Hopkins Healthcare at 1-410-424-4607. Please contact Johns Hopkins Healthcare at 1-888-819-1043 with questions regarding the Prior Authorization process.</p> <p>When conditions are met, we will authorize the coverage of Lovenox - Priority Partners MCO.</p>

Drug Name (select from list of drugs shown)	
Enoxaparin	Lovenox (enoxaparin)

Quantity	Frequency	Strength
Route of Administration	Expected Length of Therapy	

Patient Information	
Patient Name:	_____
Patient ID:	_____
Patient Group No.:	_____
Patient DOB:	_____
Patient Phone:	_____

Prescribing Physician	
Physician Name:	_____
Physician Phone:	_____
Physician Fax:	_____
Physician Address:	_____
City, State, Zip:	_____

Diagnosis: _____	ICD Code: _____
-------------------------	------------------------

Comments: _____

Please circle the appropriate answer for each question.	
1. Is this request for continuation of therapy?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.]	
[If no, then skip to question 3.]	
2. Has documentation been submitted which supports a continual medical necessity for use?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted.]	

[No further questions.]	
3. Is the patient actively bleeding?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	
4. Does the patient have a positive heparin induced thrombocytopenia (HIT) assay?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	
5. Does the patient have any known allergy or severe adverse reaction (ADR) to enoxaparin or any of its components?	<input type="checkbox"/> Y <input type="checkbox"/> N
[If yes, then no further questions.]	
6. Is the requested drug being prescribed for any of the following: A) Oncology patients with risk factors for venous thromboembolism (VTE), B) Abdominal-Pelvic surgery patients at high risk for venous thromboembolism (VTE), C) Total hip arthroplasty, D) Total knee arthroplasty, E) Hip fracture surgery, F) Deep vein thrombosis (DVT) treatment, G) Pulmonary embolism (PE) treatment, H) Superficial vein thrombosis treatment, I) Atrial Fibrillation (AF) patients undergoing cardioversion, J) Acute ischemic stroke and immobility, K) Pregnant & lactating women at high risk for venous thromboembolism (VTE) or recurrent venous thromboembolism (VTE), L) Children and infants with venous thromboembolism (VTE) or increased risk?	<input type="checkbox"/> Y <input type="checkbox"/> N
[Note: Documentation must be submitted.]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date